Moxaclav Forte Powder for Suspension (400 mg+57.50 mg)/5 ml

Moxaclav Forte is a potent antibacterial suspension containing Amoxicillin + Clavulanic Acid (400 mg + 57.50 mg)/5 ml, manufactured by Square Pharmaceuticals PLC. This powder for suspension is priced at ৳230.00 per unit, offering a cost-effective solution for bacterial infections.

It treats respiratory tract infections (sinusitis, bronchitis), urinary tract infections, skin/soft tissue infections, and bone/joint infections. The combination inhibits beta-lactamase enzymes, enhancing efficacy against resistant bacteria. Store below 25°C, refrigerate after reconstitution, and use within 7 days.

Dosage varies by age:

• Children 6-12 years: 2 teaspoons every 8 hours
• Children 1-6 years: 1 teaspoon every 8 hours
• Infants: 25 mg/kg/day of amoxicillin in divided doses

Common side effects include diarrhea, nausea, and candidiasis. Avoid with allopurinol due to allergic reaction risks. Pregnant women should use it only if absolutely necessary. For alternatives, explore other Amoxicillin + Clavulanic Acid brands.

Adults: 625mg tablet every 12hr. Children (1-12yrs): 20-45mg/kg/day in divided doses. Use reconstituted suspension within 20 minutes. Dose adjustment needed in hepatic/renal impairment. Standard treatment duration 7-14 days.

Side effects, as with Amoxicillin, are uncommon and mainly of a mild and transitory nature. Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking Co-amoxiclav at the start of meals. Hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme, Stevens-Johnson Syndrome and exfoliative dermatitis have been reported. In common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported.

Animal studies with orally and parenterally administered Co-amoxiclav have shown no teratogenic effect. The drug has been used orally in human pregnancy in a limited number of cases with no untoward effect; however, the use of Co-amoxiclav in pregnancy is not recommended unless considered essential by the physician. During lactation, trace quantities of Amoxicillin can be detected in breast milk.

Co-amoxiclav should be used with care in patients on anticoagulation therapy or with severe hepatic dysfunction. In patients with moderate or severe renal impairment, dosage should be adjusted. During the administration of a high dose of Co-amoxiclav adequate fluid intake and urinary output should be maintained to minimize the possibility of crystalluria.

The dose should be adjusted in case of patients with renal impairment

Adult:

• Mild impairment (Creatinine clearance> 30ml/minute): No changein dosage.
• Moderate impairment (Creatinine clearance 10-30 ml/minute): One 375 Tablet or one 625 Tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 12 hourly.
• Severe impairment (Creatinine clearance <10 ml/minute): Not more than one 375 mg tablet 12 hourly or 1.2 gm IV followed by 0.6 gm IV 24 hourly. Dialysis decreases serum concentrations of Moxaclav Forte and an additional 0.6 gm IV dose may need to be given during dialysis and at the end of dialysis.

Children:

• A similar reduction in dosage should be made for children.
• Administration hepatic impairment: Dose with caution; monitor hepatic function at regular intervals.

Problems of overdose with Co-amoxiclav are unlikely to occur, if encountered gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Co-amoxiclav may be removed from the circulation by haemodialysis.